Powered by: Motilal Oswal
2026-11-16 04:37:42 pm | Source: Choice Institutional Equities Ltd
Add Fineotex Chemical Ltd For Target Rs.57 by Choice Institutional Equities Ltd
Add Fineotex Chemical Ltd For Target Rs.57 by Choice Institutional Equities Ltd

Steady Quarter; Cost Control Offsets Gross Margin Pressure

FTXC’s revenue grew 3% QoQ to INR 3.9 Bn, supported by a steady performance in its core business and a flat performance from the CCT business due to lumpy order execution. Gross margin contracted ~600 bps QoQ, reflecting an unfavourable product mix and price-pass through lags. However, improved operating efficiency and normalisation of other expenses supported EBITDA margin (-33 bps QoQ). We expect margin improvement over the next few quarters, aided by better cost pass-through and rising profitability at CCT. We believe CCT’s ongoing scale-up, expansion into advanced water treatment and growing international presence will support sustained earnings growth over the medium term.

Key Risks to our Valuation

Probably slower-than-expected CCT ramp-up, a possible slowdown in US drilling and production activity and further escalation of geopolitical tensions in West Asia

Resilient Operational Performance; EBITDA in Line with CIE Est.

* Revenue rose 3% QoQ to INR 3.9 Bn (vs CIE estimate of INR 4.0 Bn)

* EBITDA grew 1% QoQ to INR 596 Mn (in line with CIE estimate), with EBITDA margin at 15.4%

* Attributable PAT declined 11% QoQ to INR 342 Mn (vs INR 365 Mn CIE estimate), with APAT margin at 8.8%

Advanced Water Treatment Solutions to Drive Growth

FTXC is building a US water and wastewater treatment business, targeting data centres, semiconductor fabs and advanced industrial facilities. The company has signed NDAs with several Fortune 500 corporates and expects first orders in Q4FY27E. It targets asset turnover of 5–6x in this business, which it plans to fund primarily through internal accruals, and is evaluating a fund raise to pursue further inorganic growth. We believe this could strengthen FTXC’s presence in high-value specialty applications over the medium term.

View and Valuation

We have broadly maintained our FY27E estimate, incorporating Q2FY27 performance, while raising our FY28E EBITDA margin estimate by 50 bps, factoring in improving operating efficiency. Our revised estimate imply Revenue / EBITDA / Attributable PAT CAGR of 48.3% / 51.7% / 44.6% over FY26–FY29E. Based on our DCF valuation, we raise our target price to INR 57 (vs. INR 51 earlier), implying a P/E of 23.1x on FY28E & FY29E average EPS and a PEG of 0.5x. Given the upside of 14.0% to our TP, we assign an ‘ADD’ rating to FTXC.

 

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer

SEBI Registration no.: INZ 000160131

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here